Abbott Laboratories
ABT
$86.97
-0.92%
Abbott Laboratories is a diversified global healthcare leader operating primarily in the Medical Devices industry, manufacturing and marketing a broad portfolio including cardiovascular and diabetes devices, diagnostic equipment, nutritional products, and branded generic drugs. The company is a dominant market player with a century-long legacy, distinguished by its balanced portfolio across high-growth medical technology and stable consumer health segments, deriving roughly 60% of sales internationally. The current investor narrative is dominated by a significant stock price decline following a cut to its 2026 profit guidance, which has overshadowed solid quarterly earnings beats, raising concerns over near-term headwinds and creating a debate around whether the sell-off presents a long-term value opportunity given its resilient core businesses and storied dividend growth history.…
ABT
Abbott Laboratories
$86.97
Related headlines
ABT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $113.06 and implied upside of +30.0% versus the current price.
Average Target
$113.06
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$70 - $113
Analyst target range
Abbott is covered by 9 analysts, and the institutional sentiment leans bullish, as evidenced by recent reaffirmations of Buy, Overweight, and Outperform ratings from major firms like Citigroup, Barclays, and RBC Capital following the Q4 earnings report. The average analyst target price is implied by the estimated EPS average of $8.36 and the forward PE of 14.12x, resulting in a target of approximately $118.06, which represents a potential upside of 37.9% from the current price of $85.60, signaling strong conviction in a medium-term recovery. The target range, inferred from estimated EPS lows and highs of $8.01 to $8.43, suggests a relatively tight spread, indicating higher analyst consensus and conviction; the high-end scenario likely assumes successful navigation of near-term guidance cuts and sustained growth in key device franchises, while the low-end may price in prolonged margin pressure or competitive challenges.
Bulls vs Bears: ABT Investment Factors
The evidence currently tilts bearish due to the severe technical breakdown, negative momentum, and the overshadowing impact of the 2026 profit guidance cut. However, the bull case is underpinned by strong analyst conviction in a recovery, exceptional financial health, and a reasonable forward valuation. The single most important tension in the investment debate is whether Abbott's Medical Devices division can deliver sufficient growth to justify its still-elevated trailing valuation and meet forward earnings expectations, thereby reversing the powerful negative sentiment that has driven the stock to near its 52-week low.
Bullish
- Strong Analyst Conviction & Upside: The average analyst target price of $118.06 implies a 37.9% upside from the current price of $85.60, signaling strong belief in a recovery. This target is derived from a forward PE of 14.12x and an estimated EPS of $8.36, indicating expectations for a significant earnings rebound.
- Exceptional Financial Health & Cash Flow: Abbott generates substantial annual free cash flow of $7.40 billion, supporting its 54-year dividend growth streak with a 63% payout ratio. The balance sheet is robust with a low debt-to-equity ratio of 0.29 and a strong current ratio of 1.58, providing ample liquidity for growth and shareholder returns.
- Medical Devices Driving Growth: The Medical Devices segment, generating $5.68 billion in Q4 2025, is the primary growth driver, significantly outpacing other divisions. This positions Abbott's future on high-margin medical technology innovation, which is critical for sustained revenue growth beyond the current 4.4% YoY pace.
- Attractive Forward Valuation: The forward PE of 14.12x is a significant discount to the trailing PE of 33.55x, reflecting market expectations for a sharp earnings recovery. This forward multiple suggests the stock is reasonably priced if the company can meet its earnings guidance and overcome near-term headwinds.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 35.57% over the past year and trading just 10.4% above its 52-week low of $81.97. Momentum remains negative with a 26.43% decline over the past three months, indicating deep investor pessimism and a lack of near-term catalysts.
- Elevated Trailing Valuation: Despite the price decline, the trailing PE of 33.55x remains elevated compared to sector averages and the stock's own historical range. This suggests the market may still be pricing in overly optimistic expectations, leaving room for further multiple compression if growth disappoints.
- Profit Guidance Cut & Margin Pressure: The recent cut to 2026 profit guidance has overshadowed solid earnings beats, raising concerns about near-term headwinds. Q4 2025 operating margin of 19.64% was down from 20.59% in the prior-year quarter, indicating potential cost pressures or unfavorable product mix shifts.
- Weak Relative Performance: Abbott has shown extreme negative relative strength, underperforming the S&P 500 by 36.71 percentage points over the past three months. This severe underperformance during a bull market suggests company-specific issues are driving the sell-off, not just broader market conditions.
ABT Technical Analysis
The prevailing price trend for Abbott Laboratories is a pronounced and sustained downtrend, with the stock down 35.57% over the past year and currently trading at a price of $85.60, which is just 10.4% above its 52-week low of $81.97, positioning it near the absolute bottom of its annual range and signaling deep investor pessimism. Recent momentum shows continued severe pressure, with the stock down 26.43% over the past three months and a further 6.27% decline over the past month, indicating the downtrend is not only intact but accelerating, starkly contrasting with the S&P 500's positive returns over the same periods and resulting in extreme negative relative strength readings of -36.71 and -12.58, respectively. Key technical support is clearly defined at the 52-week low of $81.97, while resistance sits far above at the 52-week high of $139.06; a breakdown below support would signal a capitulation phase and potential for further declines, while the stock's low beta of 0.647 indicates it has been significantly less volatile than the broader market during this sell-off, which may offer some downside protection but also suggests limited explosive recovery potential without a fundamental catalyst.
Beta
0.65
0.65x market volatility
Max Drawdown
-40.2%
Largest decline past year
52-Week Range
$82-$139
Price range past year
Annual Return
-34.9%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +5.4% |
| 3m | -23.1% | +10.9% |
| 6m | -30.6% | +11.0% |
| 1y | -34.9% | +28.1% |
| ytd | -30.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue trajectory shows modest but steady growth, with Q4 2025 revenue of $11.46 billion representing a 4.4% year-over-year increase, and segment data reveals the Medical Devices division, at $5.68 billion, is the primary growth driver, significantly outpacing the Nutritional ($1.94 billion) and Established Pharmaceuticals ($1.38 billion) segments, indicating the company's future is tied to innovation in high-margin medical technology. The company remains solidly profitable with a Q4 net income of $1.78 billion and a robust gross margin of 57.05%, though margins have shown some quarterly fluctuation, with the operating margin at 19.64% in Q4, down from 20.59% in the prior-year quarter, suggesting potential cost pressures or mix shifts that warrant monitoring for compression. Balance sheet and cash flow health are exceptional, evidenced by a strong current ratio of 1.58, a conservative debt-to-equity ratio of 0.29, and substantial annual free cash flow generation of $7.40 billion, which provides ample liquidity to fund growth initiatives, continue its 54-year dividend increase streak with a 63% payout ratio, and repurchase shares without relying on external financing.
Quarterly Revenue
$11.5B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock currently trades at a trailing PE of 33.55x, which is significantly higher than its forward PE of 14.12x, indicating the market expects a substantial rebound in earnings over the next twelve months, likely anticipating a recovery from recent headwinds. Compared to sector averages, Abbott's trailing PE of 33.55x and Price-to-Sales ratio of 4.94x are elevated, suggesting a premium valuation that the market has historically awarded for its diversified healthcare portfolio, consistent profitability, and dividend aristocrat status, though this premium has compressed dramatically during the recent sell-off. Historically, the current trailing PE of 33.55x is above the stock's own multi-year range, which has typically fluctuated between the high-teens and low-30s, indicating that even after a steep price decline, the valuation is not at bargain-basement levels and may still be pricing in optimistic expectations for a swift fundamental recovery.
PE
33.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is margin compression, as evidenced by the Q4 operating margin decline from 20.59% to 19.64% year-over-year. While revenue grew a modest 4.4% YoY, this margin pressure could accelerate if cost inflation persists or if the higher-growth Medical Devices segment faces pricing headwinds. The company's valuation also presents a risk; a trailing PE of 33.55x demands sustained growth, and any further guidance cuts could trigger significant multiple compression. The 63% dividend payout ratio, while supported by strong cash flow, leaves less flexibility if earnings decline unexpectedly.
Market & Competitive Risks: Abbott trades at a premium to sector averages with a PS ratio of 4.94x and a trailing PE of 33.55x, creating valuation compression risk if growth stock multiples contract further. The stock's low beta of 0.647 indicates it has been less volatile than the market, but this also suggests it may not participate fully in a market rally without a company-specific catalyst. Competitive risks are heightened in its key Medical Devices segment, where innovation cycles are rapid and pricing pressure is constant. The recent news of a guidance cut has already demonstrated how sensitive the stock is to perceived near-term headwinds.
Worst-Case Scenario: The worst-case scenario involves a breakdown below the key technical support at the 52-week low of $81.97, triggering a capitulation phase. This could be catalyzed by another significant earnings or guidance miss, combined with a broader market downturn. In this adverse scenario, the stock could realistically test levels implied by its maximum drawdown of -40.21%, which would translate to a price near $83.15 from its 52-week high, but given the current price, a more immediate downside target is the $81.97 low itself. From the current price of $85.60, this represents a potential loss of approximately -4.2%, but a prolonged bear case could see the stock fall toward the low end of analyst targets implied by the low EPS estimate of $8.01 and a compressed multiple, potentially resulting in a decline of 15-20%.
